Overall, gBRCA1 but not gBRCA2 carriers were at higher risk of developing grade 3–4 neutropenia and requiring G-CSF to complete their adjuvant or neoadjuvant chemotherapy (Table 3). The gene discussed is CSF3; the disease is Decreased total neutrophil count.